Страна: Индонезия
Език: индонезийски
Източник: Badan Pengawas Obat dan Makanan RI - Indonesian Food and Drug Supervisory Agency
ANAGRELIDE HYDROCHLORIDE
PRATAPA NIRMALA - Indonesia
ANAGRELIDE HYDROCHLORIDE
0,5 MG
KAPSUL
DUS, 1 BOTOL PLASTIK @ 100 KAPSUL
PATHEON MANUFACTURING SERVICE LLC
2018-04-23
1 AGRYLIN ® CAPSULES (anagrelide hydrochloride) RX ONLY 1. DESCRIPTION NAME: AGRYLIN ® (anagrelide hydrochloride) DOSAGE FORM: 0.5 mg capsules for oral administration ACTIVE INGREDIENT: AGRYLIN ® Capsules contain 0.5 mg of anagrelide base (as anagrelide hydrochloride). INACTIVE INGREDIENTS: Anhydrous Lactose NF, Crospovidone NF, Lactose Monohydrate NF, Magnesium Stearate NF, Microcrystalline Cellulose NF, Povidone USP. PHARMACOLOGICAL CLASSIFICATION: Platelet-reducing agent. CHEMICAL NAME: 6,7-dichloro-1,5-dihydroimidazo[2,1-b]quinazolin-2(3H)-one monohydrochloride monohydrate. MOLECULAR FORMULA: C 10 H 7 Cl 2 N 3 O•HCl•H 2 O MOLECULAR WEIGHT: 310.55 STRUCTURAL FORMULA: APPEARANCE: Off-white powder. SOLUBILITY: Water .................................... Very slightly soluble DimethylSulfoxide ................. Sparingly soluble Dimethylformamide ............... Sparingly soluble 2. INDICATIONS AND USAGE AGRYLIN ® Capsules are indicated for the treatment of patients with thrombocythemia, secondary to myeloproliferative disorders, to reduce the elevated platelet count and the risk of thrombosis and to ameliorate associated symptoms including thrombohemorrhagic events _[see CLINICAL STUDIES (11) and DOSAGE AND ADMINISTRATION (3)]_. 3. DOSAGE AND ADMINISTRATION 3.1 DOSAGE Treatment with AGRYLIN ® Capsules should be initiated under close medical supervision. DISETUJUI OLEH BPOM: 31/08/2021 ID: EREG10019112100197 2 Adult and Elderly The recommended starting dosage of AGRYLIN ® is 0.5 mg four times daily or 1 mg twice daily (2 capsules of 0.5 mg twice a day). Pediatrics There are limited data on the appropriate starting dose for pediatric patients. Starting doses in pediatric patients have ranged from 0.5 mg per day to 0.5 mg four times daily, so an initial dose of 0.5 mg per day is recommended. Hepatic Impairment It is recommended that patients with moderate hepatic impairment start anagrelide therapy at a dose of 0.5 mg/day and be maintained for a minimum of one week with careful monitoring of cardiovascular Прочетете целия документ